Investor Relations

Board Committees The Group has established Committees under the Board, including Audit Committee, Remuneration Committee and Nomination Committee,Strategic Investment Committe.The committees will operate in accordance with the power and rules established by the Board.

Audit Committee The Group has established an Audit Committee and has entered into a written term of power pursuant to Rule 3.22 and paragraph D.3 of the Corporate Governance Code. The Audit Committee comprises three members: Mr. Liu Teng, Mr. Cao Dequan and Ms. Yang Xiaofen. Mr. Liu Teng, possessing appropriate accounting and financial management expertise, serves as Chairman of the Committee. The Audit Committee is primarily responsible for monitoring the financial reporting, audit, internal control mechanisms and compliance with laws and regulations, appointing external auditors, and performing other duties and responsibilities appointed by the Board from time to time.

Remuneration Committee The Group has established a Remuneration Committee and has entered into a written term of power pursuant to Rule 3.25 and paragraph E.1 of the Corporate Governance Code. The Remuneration Committee comprises three members: Mr. Cao Dequan, Mr. Fu Haishu and Mr. Liu Teng. Mr. Cao Dequan serves as Chairman of the Committee. The Remuneration Committee is primarily responsible for recommending to the Board on the remuneration policies and structures for directors and senior management, establishing formal and transparent procedures for formulating remuneration policies, and making recommendations to the Board on the remuneration packages and employee benefits arrangements for directors and senior management. It also assesses the performance of executive directors, approves the terms of service contracts, and reviews and/or approves matters relating to share schemes under Chapter 17 of the Listing Rules.

Nomination Committee The Group has established a Nomination Committee and has entered into written terms of power pursuant to Rule 3.27A and paragraph B.3 of the Corporate Governance Code. The Nomination Committee comprises three members: Mr. Fu Haishu, Mr. Cao Dequan, and Ms. Yang Xiaofen. Mr. Fu Haishu serves as Chairman of the Committee. The Nomination Committee is primarily responsible for reviewing the structure, size, and composition of the Board; identifying individuals eligible to become Board members; assessing the independence of independent non-executive directors; and making selections or recommendations regarding nominated individuals for directorships and succession plans for directors (especially the Chairman and Chief Executive Officer).

Strategic Investment Committee The Group has established a Strategic Investment Committee and has entered into written terms of power. The Strategic Investment Committee comprises three members: Mr. Fu Haishu, Mr. Cao Dequan, and Ms. Yang Xiaofen. Mr. Fu Haishu serves as Chairman of the Committee. The Strategic Investment Committee is primarily responsible for reviewing and making recommendations on the company's long-term development strategy and major events, major business restructuring, mergers, divisions and dissolutions, major capital operations that require the board approval according to the articles of association, the company's business model and business development direction, targeted mergers and acquisitions projects, and any major events that may affect the company's development.

INQUIRY

Raily Aesthetic Medicine International Holdings Limited

Address: 3-5/F, Civil Aviation Building, No. 290 Zhongshan North Road, Gongshu District, Hangzhou, China

Tel: 0571-88826555 Fax: 0571-88827555

E-mail: investor.relationship@raily.com